Subject: ACC
Cantargia Approved for Listing on Nasdaq Stockholm First North Premier as Part of the Process Towards Nasdaq Stockholm's Main Market
STOCKHOLM, July 13, 2018 /PRNewswire/ -- Cantargia AB ("Cantargia"), as previously announced, intends to list the company on Nasdaq Stockholm main market in 2018. As part of the ongoing listing process, the company has been approved for listing on Nasdaq Stockholm First North Premier ("First North Premier"). First day of trading on First North Premier will be the 16 of July 2018.
The change of market place from Nasdaq Stockholm First North ("First North") to First North Premier is a natural step in the company's ongoing listing process for listing on Nasdaq Stockholm's main list. The listing process for Nasdaq Stockholm's main market is proceeding according to plan. A listing on First North Premier, in comparison with First North, implies higher disclosure requirements, accounting principles and corporate governance. The requirements of First North Premier largely correspond to the requirements on Nasdaq Stockholm's main market. Cantargia has since Q4 2017 reported financial reports according to IFRS, which is the accounting standard on Nasdaq Stockholm's main market.
The listing on First North Premier does not imply any differences for the company's shareholders. Cantargia's share will continue to be traded under the ISIN code SE0006371126 and the short name "CANTA".
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: [email protected]
About Cantargia
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company's main project, the CAN04 (nidanilimab) antibody targeted against IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 (nidanilimab) has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia's second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company's Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
These press releases may also interest you
|
News published on and distributed by:
